David Torrents

Barcelona Supercomputing Center - Centro Nacional de Supercomputación

Life & Medical Sciences

After graduating in Biochemistry and Molecular Biology, I obtained the PhD in Molecular Biology at the University of Barcelona in 2000 in the group of Manuel Palacín working on amino acid transporters and associated genetic diseases. This PhD was awarded with the University PhD Extraordinary Prize. Then I moved with an EMBO long term fellowship to the group of Peer Bork to enter in the world of genomics, at the EMBL in Heidelberg, where I stayed from 2000 to 2006. There, I worked on genome annotation and analysis using bioinformatics approaches. Currently, since 2006, I'm group leader at the Barcelona Supercomputing Center doing research on computational biomedicine.

Research interests

Genomes are the central molecules of life because they carry all the information necessary for the development, the survival and the reproduction of all organisms.  Over the lasts 20 years, the study of the genome in a biomedical context has provided valuable information about the genetic and molecular basis of diseases. Current sequencing of DNA allows the incorporation of the genome analysis as an integrated and regular protocol within the health-care system, resulting in a Precision Medicine, where the genomic information will be determinant for a more accurate diagnosis and for the selection of a more precise treatment. In this context, our group and my research activity is focused on the understanding the relationship between genomic variation and disease, in order to generate the basis for more precise medical care.  

Selected publications

- Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur I C, Rodriguez-Fos E, Gonzalez S, Puiggros M, Blackford AN, Mason CE, de Stanchina E, Gonen M, Emde A-K, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA & Kentsis A 2017, 'PGBD5 promotes site-specific oncogenic mutations in human tumors', Nature Genetics, 49, 7, 1005.

- Chinnaswamy S, Wardzynska A, Pawelczyk J, Skaaby T, Mercader JM, Ahluwalia TS, Grarup N, Guindo-Martinez M, Bisgaard H, Torrents D, Linneberg A, Bønnelykke K & Kowalski ML 201, 'A functional IFN-λ4-generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma', ​Sci Rep. 7(1):10500.

- Mercader JM, Liao RG, Bell AD, Dymek Z, Estrada K, Tukiainen T, Huerta-Chagoya A, Moreno-Macías H, Jablonski KA, Hanson RL, et al, ... & Florez JC 2017, 'A Loss-Of-Function Splice Acceptor Variant in IGF2 is Protective for Type 2 Diabetes', Diabetes, 66, 11, 2903 - 2914.

- Beekman R, Russinol N, Chapaprieta V, Verdaguer-Dot N, Vilarrasa-Blasi R, Clot G, Duran-Ferrer M, Kulis M, Castellano G et al... & Martin-Subero I 2017, 'INTEGRATIVE ANALYSIS OF THE GENOME, EPIGENOME, TRANSCRIPTOME AND THREE-DIMENSIONAL CHROMATIN STRUCTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA', Haematologica, 102, 9 - 10.

- Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Stahlman M et al, ... & Backhed F 2017, 'Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug', Nature Medicine, 23, 7, 850 - +.